Dabur India Ltd braved the inflationary pressures, significant moderation in industry growth and dip in overall consumer sentiments to deliver a competitive growth of 3.4% in Consolidated Revenue for the third quarter of 2022-23 at Rs 3,043 crore.

Consolidated Net Profit for the third quarter stood at Rs 476 crore with the 3-year CAGR at 6.1%.

India’s leading Science-based Ayurveda major Dabur India Ltd today reported a 3.4% growth in Consolidated Revenue for the Quarter ended December 31, 2022, to cross the Rs 3,000-crore mark for the time in a quarter, despite a highly challenging cost and operating environment. Consolidated Revenue posted a constant currency growth of 5.7%.
 
The Board of Directors of Dabur India Ltd met to consider the unaudited financial results of the company for the third quarter of 2022-23.
 
Dabur India Ltd braved the inflationary pressures, significant moderation in industry growth and dip in overall consumer sentiments to deliver a competitive growth of 3.4% in Consolidated Revenue for the third quarter of 2022-23 at Rs 3,043 crore. The International Business reported a 14% growth in constant currency terms. Consolidated Revenue posted a 3-year CAGR of 9%, reflecting the remarkable agility and resilience the business continues to demonstrate even in tough conditions.
 
Consolidated Net Profit for the third quarter stood at Rs 476 crore with the 3-year CAGR at 6.1%.

“We have delivered steady results in what continues to be a difficult cost and operating environment. We continued to adjust prices responsibly to reflect inflation. Our India business reported a growth of 3.3% with a 3-year CAGR of 9.5% and steady market share gains across portfolio, despite most operating categories reporting a decline,” Dabur India Ltd Chief Executive Officer Mr. Mohit Malhotra said.